SRR15030859
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.560
- MYC_TARGETS_V2+0.550
- MYC_TARGETS_V1+0.530
- G2M_CHECKPOINT+0.480
- OXIDATIVE_PHOSPHORYLATION+0.330
- DNA_REPAIR+0.260
- MTORC1_SIGNALING+0.230
- UNFOLDED_PROTEIN_RESPONSE+0.200
- SPERMATOGENESIS+0.170
- MITOTIC_SPINDLE+0.150
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.610
- ANGIOGENESIS-0.550
- COAGULATION-0.440
- INTERFERON_GAMMA_RESPONSE-0.430
- TGF_BETA_SIGNALING-0.410
- INTERFERON_ALPHA_RESPONSE-0.400
- UV_RESPONSE_DN-0.370
- HEDGEHOG_SIGNALING-0.350
- COMPLEMENT-0.340
- IL6_JAK_STAT3_SIGNALING-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 085e4228-8ed7-44d7-9ab5-8a096434b650 | — | — | 0.941 |
| 2 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.926 |
| 3 | BS_TZVFR600 | medulloblastoma | — | 0.926 |
| 4 | 3d1f89ec-ac0b-40f8-ac89-ed0c2d4967b7 | — | — | 0.924 |
| 5 | SRR8518169 | — | E | 0.923 |
| 6 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.921 |
| 7 | BS_9NZ2D6AD | medulloblastoma | — | 0.920 |
| 8 | BS_HE57E1RP | medulloblastoma | — | 0.919 |
| 9 | TCGA-21-1080-01A-01R-0692-07 | — | cohortSQ1 | 0.917 |
| 10 | C3L-00993 | — | cohortSQ1 | 0.917 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.230 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.150 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.010 | Inavolisib | — uncovered |